Drugs / ChAdOx1.HIVconsv62
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06484335 | Mar 2025 → Jul 2029 expected | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05604209 | Oct 2022 → Sep 2024 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07054931 Comparator | Sep 2025 → Oct 2027 expected | HIV infectious disease | University of Oxford | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1.HIVconsv62 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05604209 ↗ |
| Known as | C62 | “ChAdOx1.HIVconsv62 (C62) vaccine administered at Day 0, followed by MVA.tHIVconsv4 (M4) vaccine administered at Day 28” NCT05604209 ↗ |
| Modality | Vaccine | “ChAdOx1.HIVconsv62 (C62) vaccine” NCT05604209 ↗ |